Long-term treatment of cancer-prone germline PTEN mutant mice with low-dose rapamycin extends lifespan and delays tumour development.

Autor: Tibarewal P; Cancer Institute, University College London, London, UK., Rathbone V; Cancer Institute, University College London, London, UK., Constantinou G; Cancer Institute, University College London, London, UK., Pearce W; Cancer Institute, University College London, London, UK., Adil M; Cancer Institute, University College London, London, UK., Varyova Z; Cancer Institute, University College London, London, UK., Folkes L; Oxford Institute of Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Hampson A; Oxford Institute of Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Classen GAE; Cancer Institute, University College London, London, UK., Alves A; Cancer Institute, University College London, London, UK., Carvalho S; Cancer Institute, University College London, London, UK., Scudamore CL; Exepathology, Exmouth, UK., Vanhaesebroeck B; Cancer Institute, University College London, London, UK.

Publikováno v: The Journal of pathology [J Pathol] 2022 Dec; Vol. 258 (4), pp. 382-394. Date of Electronic Publication: 2022 Oct 31.